Founded in China in 2009, CanSino Biologics Inc. (CanSinoBIO) is an industry-leading biopharmaceutical company, dedicated to providing solutions for the prevention and treatment of infectious diseases globally, through research & development, manufacturing and commercialization of innovative high-quality and affordable vaccine products for human use.
CanSinoBIO has been listed on the Main Board of Hong Kong Exchanges and Clearing Limited (HKEX: 6185.HK) and on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (STAR Market, SSE: 688185), making it the first "A+H" dual-listed vaccine company in China. Currently, our launched products include Menhycia® [Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)], Menphecia® [Groups A and C Meningococcal Polysaccharide Conjugate Vaccine (CRM197)], Convidecia Air® [Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation], Convidecia® [Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)], and Ad5-EBOV [the recombinant Ebola virus vaccine]. At present, the Company is developing and conducting clinical trials of several products including first-in-class vaccines in China and globally innovative vaccines. CanSinoBIO has developed five key platform technologies, including Adenovirus-based viral vector technology, Synthetic biotechnology, Protein structure design and VLP assembly, mRNA and LNP technology as well as Formulation and drug delivery technology. In addition, the Company owns core intellectual property rights and proprietary technologies related to vaccine products. CanSinoBIO has established a rich portfolio of a pipeline products preventing more than ten diseases, including meningitis, pneumonia, pertussis, diphtheria, tetanus, COVID-19, tuberculosis, shingles, Ebola virus disease etc., and is participating in innovative R&D collaboration with multiple research institutions across the world. We have constructed large-scale manufacturing bases in Tianjin and Shanghai, with a floor area of over 100,000 square meters. Both have been designed and constructed, and are operating in accordance with international standards to manufacture multiple novel vaccines. In addition, local fill-and-finish production lines have been set up in Mexico, Pakistan, and Malaysia to establish joint manufacturing. Our well-established marketing and supply system covering Asia, Latin America, Africa, and other regions ensures the rapid distribution of vaccine products worldwide. As a leading enterprise in R&D of innovative vaccine, we are committed to the guard of global public health through the fulfillment of our social and international responsibilities, and the development and supply of high-quality vaccine products, contributing to the global public health programs.
Dr. Yu is primarily responsible for overseeing strategic development, overall operation and management and major decision-making of our Group. He obtained a bachelor’s degree in Biology and a master's degree in Microbiology from Nankai University in July 1985 and June 1988, respectively. He obtained a Ph.D in Microbiology from McGill University in June 1998. He has more than 30 years' experience in biotech R&D. Prior to founding our Company, Dr. Yu worked for Sanofi Pasteur Limited, director of the Canadian division of bacterial vaccine development and global director of bacterial vaccine development. Dr. Yu has extensive experience in the development of biological products, enterprise operation and management. For more than 10 years, Dr. Yu has attracted senior talents from the vaccine industry in China and abroad to assemble a team of cutting-edge experts for the Company. Under his leadership, the Company has developed a rich pipeline for various vaccines covering more than 10 infectious diseases. As the Chairman and CEO of the Company, Dr. Yu has strategically positioned the Company to become a China and Hong Kong dually listed company from the perspective of corporate development, raising significant amount of proceeds to support Company's development.
Dr. Chao was appointed as the chief operating officer in 2018. He is primarily responsible for management of daily operations and strategic development of our Group, including production management, quality control, supply chain management and information system construction. Dr. Chao received a bachelor's degree in inorganic chemical engineering from Jiangxi Institute of Technology, a master's degree in chemical metallurgy from the Chinese Academy of Sciences, and a Ph.D in biochemical engineering from the University of Waterloo, Canada. With over 30 years' experience in the biotechnology industry, prior to joining the Company, he worked for Sanofi Pasteur, Pfizer, AstraZeneta and other world-renowned multinational pharmaceutical companies, serving as technical and senior management positions. He has extensive experience in R&D, production, supply chain, quality assurance and commercialization in the field of vaccines and biopharmaceuticals, especially in large-scale industrial production management and global commercial operations. Dr. Chao has a deep understanding of global GMP regulations. Since joining the Company, Dr. Chao has made outstanding contributions to the Company's IPO and financing, development and production of the COVID-19 vaccine and meningococcal combined vaccines, and the establishment of a talent system. In the COVID-19 vaccine project, Dr. Chao led the commercial scale manufacturing, quality system management, talent system establishment and team expansion, to ensure that the Company launched a safe and effective, high quality COVID-19 vaccine efficiently. In addition, Dr. Chao also led in the large-scale production of COVID-19 vaccines to ensure its supply.
Dr. Zhu has served as the chief scientific officer since January 2009. He is primarily responsible for leading vaccine R&D of company. In addition, Dr. Zhu is also responsible for domestic registration and clinical affairs. Dr. Zhu received a bachelor's degree in biological sciences and technology from Tsinghua University, a master's degree in chemical engineering from Tsinghua University, a Ph.D. in chemical engineering from University of Pittsburgh, and then he conducted a postdoctoral study at Carnegie Mellon University in the United States. Dr. Zhu has more than 20 years of experience in vaccine R&D and production. Prior to founding the Company, Dr. Zhu worked as a scientist at Integrated Genomics Inc., and joined Sanofi Pasteur in 2006, where he served as a senior scientist. After the Company was founded, Dr. Zhu led the establishment of the world-class level major R&D technology platforms. He established a pipeline composed of more than ten new vaccines relying on the technology platforms, covering pneumonia, TB, Ebola virus disease, meningitis, DPT and a series of diseases. Together with external experts, Dr. Zhu led the team in developing the Ebola virus disease vaccine Ad5-EBOV, which is an innovative recombinant vaccine product independently developed in China with fully independent intellectual property rights. After the outbreak of COVID-19, Dr. Zhu once again worked with external experts to develop the COVID-19 vaccines, and make the vaccine globally leading in development speed and clinical trial results. In addition, Dr. Zhu led the development of two new meningococcal binding vaccine, which has been commercialized to fill the vacancy in the domestic market. In addition, the Company also has PBPV, PCV13i, the DTcP vaccines, TB Booster and other innovative vaccines that are in clinical trial stage. Dr. Zhu has various patents of inventions in China and abroad.
Ms. Jeanne Wang was appointed as Chief Commercial Officer in September, 2021, responsible for the company's overall commercial operation in both China and Overseas markets. Ms. Wang has more than 20 years experience in pharmaceutical industry, she holds a bachelor degree in Economics, a master degree in engineering of Peking University and Global EMBA of CEIBS. After joining the Company in June 2012, Ms. Wang has made outstanding achievements in previous positions such as Head of HR&Admin, VP of Strategy and Business Development, Board Secretary and Chief Financial Officer. Ms. Wang has led the establishment of company’s financing, financial operations, human resource and administration systems, as well as completing several rounds of Pre-IPO fund raising. Ms. Wang successfully led the Company’s IPO on Main Board of Hong Kong Stock Exchange in 2019 and on the Sci-tech Innovation Board of the Shanghai Stock Exchange in August 2020, making the Company the first “A+H” dual listing vaccine company.
Dr. George Siber is an infectious disease trained physician with 40 years' experience in developing vaccines and antibody products. Dr. George Siber was an Associate Professor of Dana Farber Cancer Institute at Harvard Medical School and Director of the Massachusetts Public Health Biologic Laboratories. Currently, he is an Adjunct Professor of Medicine at Johns Hopkins Medical School. Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (Pfizer) 1996-2007, leading the development and approval of multiple childhood vaccines including Prevenar 7 and 13. Currently, Dr. Siber is a Co-founder and Board Member of Affinivax and a Board Member of Genocea Biosciences and serves on multiple Scientific Advisory Boards including AdVaccine, Everest, Clover, ILiAD, Valneva, Vaxart and Vaxxinity. Dr. Siber has received multiple awards including the Albert Sabin Gold Medal in vaccinology in 2016.
Dr. Luis Barreto is the President of Dr. Luis Barreto & Associates. Dr. Barreto is a member of the International Advisory Board of the McMaster/Maastricht/Manipal Global Health Program, a member of the Scientific Advisory Board for the Human Health Therapeutics Group of the National Research Council (NRC), Canada, a Senior Scientifc Advisor to Inventprise/InventVac U.S./Canada. Dr. Barreto was formerly Vice-President of Clinical, Medical and Regulatory Affairs, Vice-President of Immunization and Science Policy, and a member of the Senior Management Team at Sanofi Pasteur Canada, as well as a member of its Global Public Policy group. He spent more than 23 years in research and development, leading Phase I-IV clinical trials, licensing and launching vaccines globally. Dr. Barreto has been/is on many volunteer boards of directors, including VIDO-InterVAC (Chair), Research Canada, March of Dimes. He has been/is on many advisory review panels for the Tri Council (CIHR, NSERC and CFI) with the government of Canada and Not for Profit organisations. He has also been member of two panels of the Council of Canadian Academies, Canada.
Prof. Dr. Pierre Van Damme obtained his PhD in epidemiology and public health in 1994. He was for more than 35 years active in vaccine, clinical trial and infectious disease research. Since 2000, he is full professor in Vaccinology at the University of Antwerp, Faculty of Medicine and Health Sciences. Dr. Van Damme is the founder and director of the Centre for the Evaluation of Vaccination (CEV, University of Antwerp), a World Health Organization (WHO) Collaborating Centre for the control and prevention of infectious diseases in European region. Dr. Van Damme has been for more than 25 years a regular advisor for national and international organizations, including the National Immunization Technical Advisory Group, and the WHO. He has been appointed as chairman of the European Technical Advisory Group of Experts on communicable diseases and vaccines for the WHO European Region (ETAGE) (2005-2015).
Prof. David Salisbury was Director of Immunisation at the Department of Health and has chaired the Strategic Advisory Group of Experts on immunisation for the World Health Organisation (WHO). He has led the introduction of a large number of new immunisation programmes and vaccines. The UK immunisation programme is one of the foremost in the world and its excellence is recognised in both developed and developing countries. He has demonstrated that the successful immunisation programmes require the collaboration of science, policy development, strategy and implementation, and whose impact has been the saving of thousands of lives. He is the Chair of the Jenner Vaccine Foundation and is a Board Trustee of the Sabin Vaccine Institute. Prof. David Salisbury is also Chair of the WHO Global Commission for Certification of Poliomyelitis Eradication.
Prof. Jingren Zhang is the professor of Medical School in Tsinghua university, mainly focusing on the molecular mechanism of acute pneumonia and related diseases. Prof. Zhang obtained his doctorate in microbiology from the University of Texas Health Science Center-Houston in 1997. During 1998 to 2000, he worked as a postdoctoral fellow in the department of infectious diseases at St. Jude Children's Research Hospital. Prof. Zhang worked in the China Agricultural University, associate professor from Albany Medical College, US and a visiting professor by institute of microbiology, Chinese Academy of Sciences.
CanSinoBIO is committed to building an outstanding reputation through strict adherence to the law.
Integrity, ethics, and compliance are fundamental to our sustainable success and essential for maintaining public trust and recognition.
津公网安备12011602300399
